24 May 2013
Keywords: Spectrum, Fusilev, FDA Response, Colorectal cancer
Article | 12 October 2009
California, USA-based Spectrum Pharmaceuticals says that it received a Complete Response letter from the Food and Drug Administration regarding its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 October 2009
23 May 2013
© 2013 thepharmaletter.com